Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 8Neoplasms 7Colorectal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 5Breast Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Glioma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Hematologic Neoplasms 3

Interventions

trametinib 1dabrafenib 1Vincristine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × Astrocytoma × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡